Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187466 · ClinicalTrials.gov registry record · Phase 4
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
A Phase 4 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 4
- Development phase
- 146
- Enrollment target
NCT07187466: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT07187466 is a Phase 4 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 146 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07187466, a Phase 4 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also want to find out what factors influence whether someone responds to the treatments.
Primary Outcome
The primary outcome measure at 12 weeks will be urinary symptom severity as measured by the International Consultation on Incontinence Questionnaire-Overactive Bladder module (ICIQ-OAB). Scores range from 0 to 16 with higher scores indicating worse symptom frequency. The symptom score will be collected at 3 time points during the study: baseline, 6-weeks, and 12-weeks.
Interventions
- DRUG mirabegron
- BEHAVIORAL Exercise-based behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 4 |
What is known before NCT07187466 opens enrollment
NCT07187466 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which mirabegron is the first listed.
NCT07187466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07187466 about?
NCT07187466 is a clinical study titled "Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease". The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also w...
What is the current status of trial NCT07187466?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 146 participants. The study started on 2026-07-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT07187466?
The interventions under investigation include: mirabegron (DRUG), Exercise-based behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT07187466?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07187466's enrollment target sits among peer trials
146 571st of 2000 higher than 1,428 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI